Biotech funding has returned. The bar has moved with it.

In the years following the COVID-19 pandemic, the firms working closest to biotech investment were calling it a “nuclear winter.” Deal-making had stalled, investment committees had gone quiet, and early-stage activity had nearly stopped entirely. Today, that same corner of the market is closing its third consecutive quarter of historic activity, with renewed confidence translating into drug development, not just deal flow.

For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding, because what this cycle looks for is meaningfully different from the past. While capital is more available, it is being directed toward a narrower definition of value, and companies who read the recovery as permission to move fast and figure out the rest later are misunderstanding its signals.

What the market is selecting for

Not all assets are being funded equally right now. Investment is flowing toward high value-driving assets that address a clear unmet need or can quickly demonstrate value. What makes this moment distinct is that investors are not the only ones applying this filter. Regulators and payers are converging around the same definition of value, and that convergence is shaping which assets are genuinely fundable, not just at the financing stage, but throughout development. The core disconnect is that many sponsors are still optimising for approvability, when the market is now rewarding integrated, globally viable, reimbursement-ready value from the outset.

That disconnect is already visible in the market. Some programmes clear regulatory milestones, but struggle to generate commercial pull because the evidence package does not support meaningful differentiation, payer confidence, or adoption at the intended price. Others have a compelling market narrative, but the regulatory or clinical evidence requirements are more demanding than initially assumed. These misalignments can mean trial redesigns or additional evidence-generation requirements, which can lead to lower valuations or weaker partnering leverage.

On the commercial side, the significant pressure coming to bear on reimbursement and pricing is favouring assets that can clearly demonstrate value and address unmet need. As investment returns, so does caution about how that money is being spent. Historically, the loosening of the purse strings in biotech has encouraged hiring up, investing in fixed assets, moving quickly without the discipline the development path actually demands. The biotech sponsors who repeat those patterns in this cycle will risk building programmes that lose fundability as they advance, not because the science faltered, but because their value story was never clearly constructed.

We are seeing sponsors coming to us earlier with questions that historically would have been addressed later: whether the target product profile can justify the intended price, whether the endpoints will matter to payers, or whether the comparator strategy is strong enough.

In some cases, those answers are forcing a rethink of the development plan itself. A broad indication strategy may need to be narrowed to a population with clearer unmet need. Endpoints may need to be revised or supplemented to demonstrate value beyond clinical response. Indication sequencing may need to change to build a stronger access and pricing story.

The cost of regulatory missteps in this environment

More capital does not make the regulatory or commercial path easier; if anything, it raises the stakes. Biotech sponsors must ensure that it is being deployed against development plans that are realistic, evidence-driven, and capable of holding up under scrutiny across regulatory, clinical, and commercial dimensions. The distinction that matters is between advancing a programme and building evidence of its value. Clinical protocols need to be designed with the end in mind, with endpoints chosen not simply to clear the next technical hurdle, but to support the commercial value proposition and generate the kind of evidence that will hold up with payers, regulators, and in the next financing round. Endpoints that serve advancement, but not evidence of value will eventually encounter a wall.

The operational reality of a constrained FDA is not just longer timelines, although, delays and variability are certainly part of the concern. The bigger issue is that sponsors have fewer opportunities to work through ambiguity. A constrained FDA can mean longer response cycles, more limited informal interaction, more pointed information requests, and less tolerance for incomplete evidence packages. For sponsors, that makes the first submission, the first major meeting package, and the first pivotal study design much more consequential.

The cost of regulatory missteps can be substantial. Sponsors may need to amend protocols, add cohorts, revisit endpoints, generate additional CMC or nonclinical work, or delay pivotal trial initiation. Those changes consume capital and time, but they also affect credibility. In this funding environment, a regulatory misstep can become a valuation issue, a partnering issue, or a financing issue very quickly.

Build evidence, not just momentum

The rebound in biotech funding presents a genuine opportunity. But it should not be mistaken as a return to the loose logic of prior cycles, where capital availability created permission to grow first and optimise later. The companies that treat it that way, moving quickly without the discipline this environment requires, will likely find it harder to secure funding, defend pricing, and hold up under regulatory scrutiny.

Instead, the biotech sponsors best positioned for this new environment will be those who use funding to build sharper strategies that meet every clinical, regulatory, and commercial dimension the market now demands. Because the bar has moved and recognising that early can be a biotech sponsor’s biggest competitive advantage.

About the author

Paul Bridges is president of Parexel Consulting, comprising Access Consulting, Regulatory Consulting, Strategic Compliance, Medical Communications – as well as Health Advances and The Medical Affairs Company (TMAC). In this role, he leads a global team of more than 2,100 colleagues, including former regulators and HTA professionals. In his nearly two decades with Parexel, Bridges’ experience includes serving as VP, European account management for Parexel Consulting, as well as senior director of the regional UK Integrated Product Development (IPD) team. He joined the organisation as a principal consultant, providing strategic regulatory advice on all aspects of drug development ,with a special focus on Chemistry, Manufacturing and Controls (CMC). He has extensive knowledge of European licensing procedures from the perspective of both industry and regulatory authorities covering diverse therapeutic areas. As part of his PhD programme, Bridges studied the pulmonary delivery of drugs and has published work in this field. He is a member of the British Institute of Regulatory Affairs, the European Society of Regulatory Affairs, the Royal Pharmaceutical Society of Great Britain, and the Royal Society of Medicine.